Generation Bio (GBIO)

• Market cap: $58.8M
• 1 day: -4.35%
• 5 days: -16.98%
• 1 month: -24.14%
• 3 months: -64.08%
• 6 months: -69.97%
• Year to date: -20.72%
• 1 year: -51.11%
• 5 years: -96.44%
• 10 years: -96.44%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Employees: 174

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

2.05% less ownership

Funds ownership: 85.06% [Q2] → 83.02% (-2.05%) [Q3]

3% less funds holding

Funds holding: 79 [Q2] → 77 (-2) [Q3]

14% less capital invested

Capital invested by funds: $160M [Q2] → $137M (-$22.8M) [Q3]

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

31% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 29

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8 809% upside
• Avg. target: $8 809% upside
• High target: $8 809% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Needham Gil Blum 23% 1-year accuracy 39 / 172 met price target

809% upside $8

Buy Maintained

8 Jan 2025